Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01771731 · ClinicalTrials.gov registry record · Phase 1
Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01771731 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 27 participants.
The verdict
NCT01771731, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opioids. The investigators will also assess the clinical safety of the concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the short-term side effects associated with combined therapy. Finally, the investigators will evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease progression in patients with SCD. Hypotheses are as follows: 1. Inhaled cannabis will significantly reduce chronic pain in patients with SCD. 2. Inhaled cannabis will significantly alter the short-term side effects experienced by patients who take opioids for SCD. 3. Inhaled cannabis will significantly alter markers of inflammation and disease progression in patients with SCD compared to placebo.
Interventions
- DRUG Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01771731
The ClinicalTrials.gov registry entry for NCT01771731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabis is the first listed.
NCT01771731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01771731 about?
NCT01771731 is a clinical study titled "Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease". Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opio...
What is the current status of trial NCT01771731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-08. Estimated completion is 2017-05-19.
What interventions are being tested in trial NCT01771731?
The interventions under investigation include: Cannabis (DRUG).
Who is sponsoring clinical trial NCT01771731?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.